Hemophilia Federation of America is a national nonprofit organization that assists, educates and advocates for the bleeding disorders community.
March 12, 2019
A subcutaneous, bi-specific antibody therapy becomes commercially available to those with hemophilia A and inhibitors. This product gets approval for hemophilia A patients a year later.
Sign up for E-mails, Dateline Magazine, and other ways to stay connected.
© 2022 Hemophilia Federation of America
▪ All rights reserved
▪ Privacy & Social Media Statements